The role of pediatricians as key stakeholders in influencing immunization policy decisions for the introduction of meningitis B vaccine in Canada: The Ontario perspective

Canadian Journal of Infectious Diseases and Medical Microbiology

Volumn 26, Issue 4, 2015, Pages 183-190

  Yamashiro, Hirotaka ^a   Cutcliffe, Nora ^a   Dobson, Simon ^a   Fisman, David ^a   Gold, Ronald ^a  

^a Ontario Medical Association and Pediatricians Alliance of Ontario 'Pediatricians of Ontario   (Canada)

Author keywords

4CMenB vaccine; Immunization policy; Invasive meningococcal disease (IMD); Pediatricians; Preventive care; Serogroup B

Indexed keywords

MENINGITIS B VACCINE; MENINGITIS VACCINE; UNCLASSIFIED DRUG;

ARTICLE; BACTERIAL STRAIN; CANADA; CHILD HEALTH CARE; CLINICAL PRACTICE; COST EFFECTIVENESS ANALYSIS; DOCTOR PATIENT RELATION; ECONOMIC ASPECT; EPIDEMIOLOGY; ETHICS; HEALTH CARE COST; HEALTH CARE POLICY; HIGH RISK POPULATION; HUMAN; IMMUNIZATION; INFECTION PREVENTION; INVASIVE MENINGOCOCCAL DISEASE; LABORATORY TEST; LEGAL ASPECT; MEDICAL DECISION MAKING; MEDICAL SOCIETY; MENINGOCOCCOSIS; NEISSERIA MENINGITIDIS; PARENTAL BEHAVIOR; PEDIATRICIAN; POLITICS; POLYMERASE CHAIN REACTION; PRACTICE GUIDELINE; PREVENTIVE HEALTH SERVICE; VACCINATION;

EID: 84950315171     PISSN: 17129532     EISSN: 19181493     Source Type: Journal    
DOI: 10.1155/2015/963940     Document Type: Article

References (67)

1. Scheifele DW, Ward BJ, Halperin SA, McNeil SA, Crowcroft NS, Bjornson G. Approved but non-funded vaccines: Accessing individual protection. Vaccine 2014;32:766-70.
2. Freed GL, Clark SJ, Butchart AT, Singer DC, Davis MM. Sources and perceived credibility of vaccine-safety information for parents. Pediatrics 2011;127(Suppl 1):S107-S12.
3. Pediatrics Section of the Ontario Medical Association (PSOMA). (Accessed February 27, 2015).
4. Pediatricians Alliance of Ontario (PAO). (Accessed February 27, 2015).
5. Novartis Press Release. Health Canada approves Bexsero, the first vaccine available to prevent meningococcal serogroup B (MenB). December 9, 2013. (Accessed February 27, 2015).
6. Meningococcal B pilot project task group. The recommended use of the multicomponent meningococcal B (4CMenB) vaccine in Canada: Common guidance statement. March 26, 2014. 1-76.
7. National Advisory Committee on Immunization (NACI), Advice for the use of the multicomponent meningococcal serogroup B (4CMenB) vaccine. April 2014. 1-41. ISBN 978-1-100-23516-5. (Accessed February 27, 2015).
8. Robinson JL. Immunization for meningococcal serogroup B: What does the practitioner need to know? Paediatr Child Health 2014;19:91-4.
9. Robinson J. What is new from the Canadian Paediatric Society Committee on Infectious Diseases and Immunization? Can J Infect Dis Med Microbiol 2014;25:130-2.
10. Li YA, Tsang R, Desai S, Deehan H. Enhanced surveillance of invasive meningococcal disease in Canada, 2006-2011. Public Health Agency of Canada CCDR 2014;40:160-9. (Accessed February 27, 2015).
11. Sadarangani M, Bettinger JA, Scheifele DW. How best to describe the risk of meningococcal B infection? Paediatr Child Health 2013;18:543.
12. Dang V, Jamieson F, Wilson S, et al. Epidemiology of serogroup B invasive meningococcal disease in Ontario, Canada, 2000 to 2010. BMC Infect Dis 2012;12:202.
13. Kinlin LM, Jamieson F, Brown EM, et al. Rapid identification of herd effects with the introduction of serogroup C meningococcal conjugate vaccine in Ontario, Canada, 2000-2006. Vaccine 2009;27:1735-40.
14. Bettinger JA, Scheifele DW, Le Saux N, et al. The disease burden of invasive meningococcal serogroup B disease in Canada. Pediatr Infect Dis J 2013;32:e20-e25.
15. World Health Organization. Bacterial Meningitis. (Accessed February 27, 2015).
16. World Health Organization. Meningococcal Meningitis. Fact sheet 141. November 2012. (Accessed February 27, 2015).
17. Joint Committee on Immunisation. JCVI interim position statement on use of Bexsero meningococcal B vaccine in the UK. July 2013.
18. Australian Technical Advisory Group on Immunisation (ATAGI) Statement. Advice for immunisation providers regarding the use of Bexsero-a recombinant multicomponent meningococcal B vaccine (4CMenB). March 2014. (Accessed February 27, 2015).
19. FDA News Release. FDA approves a second vaccine to prevent serogroup B meningococcal disease. Jan. 23, 2015. (Accessed February 27, 2015).
20. Joint Committee on Immunisation. JCVI position statement on use of Bexsero meningococcal B vaccine in the UK. March 2014. (Accessed February 27, 2015).
21. National Advisory Committee on Immunization (NACI). Statement on recommended use of meningococcal vaccines. CCDR 2001;27(ACS-6):2-36.
22. National Advisory Committee on Immunization (NACI). Update on the Invasive Meningococcal Disease and Meningococcal Vaccine Conjugate Recommendations. CCDR April 2009;35(ACS-3):1-40.
23. Salvadori M, Bortolussi R. Meningococcal vaccines in Canada: An update. Paediatr Child Health 2011;16:485.
24. Agence de la santé et des services sociaux du Saguenay-Lac-Saint-Jean. Communiqué. Campagne de vaccination ciblée contre le méningocoque dans la région du Saguenay-Lac-Saint-Jean. April 22, 2014. (Accessed February 27, 2015).
25. Agence de la santé et des services sociaux Québec. Targeted Meningococcal Serogroup B Vaccination Campaign in the Saguenay-Lac-Saint-Jean Region. April 2014. (Accessed February 27, 2015).
26. Acadia University students line up for meningitis vaccinations. CBC News. February 18, 2015. (Accessed February 27, 2015).
27. Major M, Moss S, Gold R. From genes to vaccine: A breakthrough in the prevention of meningococcal group B disease. Paediatr Child Health 2011;16:e61.
28. IMPACT. Canadian Immunization Monitoring Program, ACTive. Surveillance. What is IMPACT? (Accessed February 27, 2015).
29. Toronto Invasive Bacterial Diseases Network (TIBDN). Surveillance for invasive infection due to Neisseria meningitidis. (Accessed February 27, 2015).
30. Finne J, Leinonen M, Mäkelä PH. Antigenic similarities between brain components and bacteria causing meningitis: Implications for vaccine development and pathogenesis. Lancet 1983;322:355-7.
31. Bai X, Borrow R. Genetic shifts of Neisseria meningitidis serogroup B antigens and the quest for a broadly cross-protective vaccine. Expert Rev Vaccines 2010;9:1203-17.
32. Rappuoli R. Reverse vaccinology. Curr Opin Microbiol 2000;3:445-50.
33. Frosi G, Biolchi A, Sapio ML, et al. Bactericidal antibody against a representative epidemiological meningococcal serogroup B panel confirms that MATS underestimates 4CMenB vaccine strain coverage. Vaccine 2013;31:4968-74. (Accessed February 27, 2015).
34. Gossger N, Snape MD, Yu LM, et al. Immunogenicity and tolerability of recombinant serogroup B meningococcal vaccine administered with or without routine infant vaccinations according to different immunization schedules: A randomized controlled trial. JAMA 2012;307:573-82.
35. Vesikari T, Esposito S, Prymula R, al. Immunogenicity and safety of an investigational multicomponent, recombinant, meningococcal serogroup B vaccine (4CMenB) administered concomitantly with routine infant and child vaccinations: Results of two randomised trials. Lancet 2013;381:825-35.
36. Santolaya ME, O'Ryan ML, Valenzuela MT, et al. Immunogenicity and tolerability of a multicomponent meningococcal serogroup B (4CMenB) vaccine in healthy adolescents in Chile: A phase 2b/3 randomised, observer-blind, placebo-controlled study. Lancet 2012;379:617-24.
37. Frasch CE, Borrow R, Donnelly J. Bactericidal antibody is the immunologic surrogate of protection against meningococcal disease. Vaccine 2009;27(Suppl 2):B112-6.
38. Donnelly J, Medini D, Boccadifuoco G, et al. Qualitative and quantitative assessment of meningococcal antigens to evaluate the potential strain coverage of protein-based vaccines. Proc Natl Acad Sci USA 2010;107:19490-5.
39. Australian Government. Department of Health. Therapeutic Goods Administration. AusPAR Attachment 2. Extract from the Clinical Evaluation Report for Multi-Component Meningococcal B vaccine. May 3, 2013
40. Bettinger JA, Scheifele DW, Halperin SA, et al. Diversity of Canadian meningococcal serogroup B isolates and estimated coverage by an investigational meningococcal serogroup B vaccine (4CMenB). Vaccine 2013;32:124-30.
41. Rappuoli R. The challenge of developing universal vaccines. F1000 Med Rep 2011;3:16.
42. Pitman R, Fisman D, Zaric GS, et al. Dynamic transmission modeling: A report of the ISPOR-SMDM modeling good research practices task force-5. Value Health 2012;15:828-34. (Accessed February 27, 2015).
43. Delbos V, Lemée L, Bénichou J, et al. Impact of MenBvac, an outer membrane vesicle (OMV) vaccine, on the meningococcal carriage. Vaccine 2013;31:4416-20.
44. Holmes J, Martin D, Ramsay C, Ypma E, Oster P. Combined administration of serogroup B meningococcal vaccine and conjugated serogroup C meningococcal vaccine is safe and immunogenic in college students. Epidemiol Infect 2008;136:790-9.
45. Schuchat A, Messonnier NR. From pandemic suspect to the postvaccine era: The Haemophilus influenzae story. Clin Infect Dis 2007;44:817-9.
46. Kellner JD, Scheifele D, Vanderkooi OG, MacDonald J, Church DL, Tyrrell GJ. Effects of routine infant vaccination with the 7-valent pneumococcal conjugate vaccine on nasopharyngeal colonization with Streptococcus pneumoniae in children in Calgary, Canada. Pediatr Infect Dis J 2008;27:526-32.
47. Fairley CK, Hocking JS, Gurrin LC, Chen MY, Donovan B, Bradshaw C. Rapid decline in presentations of genital warts after the implementation of a national quadrivalent human papillomavirus vaccination programme for young women. Sex Transm Infect 2009;85:499-502.
48. Ali H, Donovan B, Wand H, et al. Genital warts in young Australians five years into national human papillomavirus vaccination programme: National surveillance data. BMJ 2013;346.
49. Glass RI, Patel M, Parashar U. Lessons from the US rotavirus vaccination program. JAMA 2011;306:1701-2.
50. Read R, Baxter D, Chadwick D, et al. Impact of quadrivalent conjugate (MenACWY-CRM) and serogroup B (4CMenB) meningococcal vaccines on meningococcal carriage in English university students (Abst). Meningitis and septicemia in children and adults 2013; London, England. November 2013.
51. Tuite AR, Fisman DN. Number-needed-to-vaccinate calculations: Fallacies associated with exclusion of transmission. Vaccine 2013;31:973-8. (Accessed February 27, 2015).
52. Sanchez IR, Meltzer MI, Shepard C, et al. Economics of an adolescent meningococcal conjugate vaccination catch-up campaign in the United States. Clin Infect Dis 2008;46:1-13.
53. Shepard CW, Ortega-Sanchez IR, Scott RD, Rosenstein NE, the ABCs Team. Cost-effectiveness of conjugate meningococcal vaccination strategies in the United States. Pediatrics 2005;115:1220-32.
54. Centers for Disease Control and Prevention. Serogroup B Meningococcal Vaccine and Outbreaks. (Accessed February 27, 2015).
55. Ontario Ministry of Health. Infectious Diseases Protocol. Appendix A: Disease-Specific Chapters. Chapter: Meningococcal disease, invasive. Revised January 2014. (Accessed February 27, 2015).
56. Erickson L, De Wals P, Farand L. An analytical framework for immunization programs in Canada. Vaccine 2005;23:2470-6.
57. Stanley M. Perspective: Vaccinate boys too. Nature 2012;488:S10.
58. Public Health Agency of Canada. Survey of Parents on Key Issues Related to Immunization. EKOS Research Associates Inc. September 2011. (Accessed February 27, 2015).
59. Fisher W, Bettinger J, Gilca V, et al. Understanding the impact of approved but unfunded vaccine status on parental acceptance of a novel meningococcal sergroup B vaccine for infants (Abst 0351). 32nd Meeting of the European Society for Paediatric Infectious Diseases (ESPID); Dublin, Ireland. May 8, 2014.
60. Scheifele DW, Halperin SA, Bettinger JA. Childhood immunization rates in Canada are too low: UNICEF. Pediatr Child Health 2014;19:237-8.
61. Toronto Public Health Communique. May 2014. Issue 32 CommuniqueMay2014Web.pdf> (Accessed February 27, 2015).
62. Government of Ontario. Immunization of School Pupils Act. R.R.O. 1990. REGULATION 645. (Accessed February 27, 2015).
63. Canadian Medical Protective Association (CMPA). January 2009 (IS0887-E). New vaccines-What are your obligations? An article for physicians by physicians. (Accessed February 27, 2015).
64. World Health Organization. Principles and considerations for adding a vaccine to a national immunization programme-from decision to implementation and monitoring. April 2014. (Accessed February 27, 2015).
65. Meningitis Research Foundation of Canada. (Accessed February 27, 2015).
66. Meningitis Relief. (Accessed February 27, 2015).
67. National Advisory Committee on Immunization (NACI). Update on the use of quadrivalent conjugate meningococcal vaccines. CCDR. January 2013;39(ACS-1):1-40. (Accessed February 27, 2015).